SCHEMBL18558166

SCHEMBL18558166

Cc1cc(N/C(=N\C(=O)c2ccc(F)c(F)c2)NC2CCCC2)[nH]n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
MCHR1 Q99705 4/20 0.38
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
KCNH2 Q12809 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
SSTR3 P32745 1/20 0.36
WNT1 P04628 1/20 0.36
DYRK1A Q13627 1/20 0.36
KCNQ3 O43525 2/20 0.35
KCNQ2 O43526 2/20 0.35
ACKR3 P25106 1/20 0.35
CYP1A2 P05177 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9920869 0.86 NPC1 (0.42) NPC1RAB9ASMN1; SMN2TAS1R3TAS1R1
SCHEMBL18558207 0.86 MLLT3 (0.37) NPC1RAB9ASMN1; SMN2TAS1R3TAS1R1
SCHEMBL18558490 0.85 RAB9A (0.40) NPC1RAB9ASMN1; SMN2TAS1R3TAS1R1
SCHEMBL18558421 0.85 TRPV1 (0.41) SMN1; SMN2EPHX2HTT
SCHEMBL9920911 0.84 NPC1 (0.39) NPC1RAB9ASMN1; SMN2TAS1R3TAS1R1
SCHEMBL18558211 0.84 WNT1 (0.36) NPC1RAB9ASMN1; SMN2TAS1R3TAS1R1
SCHEMBL18558297 0.83 NR1H4 (0.38) NPC1RAB9ASMN1; SMN2CYP3A4CYP2D6
SCHEMBL18558315 0.83 KDM5B (0.38) NPC1RAB9ASMN1; SMN2WNT1DYRK1A
SCHEMBL18558432 0.81 CHRNA1 (0.38) NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2
SCHEMBL18557680 0.80 RAB9A (0.48) NPC1RAB9ASMN1; SMN2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed